ClinicalTrials.gg
RecruitingNCT06991127Updated May 25, 2025

Clinical Investigation of MAIA Microperimeter Device: Mesopic Normative Database Collection

An interventional study of MAIA in Healthy Eyes, sponsored by Centervue SpA. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by Centervue SpA · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
380
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this pre-market, multicentric cross-sectional study is to create a mesopic Normative Database for a new version of the MAIA device. Moreover, the study aims to evaluate MAIA safety and adverse events. These purposes will be achieved by collecting data of healthy subjects, who will undergo microperimetric examinations with the MAIA device during one single visit.

02

Conditions studied

  • Healthy Eyes
03

In context

Lead sponsor

Centervue SpA is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: ≥18 years old;
  • Best Corrected Visual Acuity (BCVA): ≥ 0.8 Decimal (≥ 20/25 ft, ≤ +0.1 logMAR) at least in the study eye;
  • Equivalent spherical refraction between the range ≥ -6D and ≤ +6D; astigmatism within 2D (≤ 2D) at least in the study eye;
  • Intraocular Pressure (IOP) ≤ 21 mmHg in both eyes (Goldmann applanation tonometer);
  • Clinically normal appearance of the optic nerve head according to clinical judgement (no evidence of excavation, rim thinning, notching, disc hemorrhages, RNFL thinning) in both eyes. This is examined with Spectralis or Solix OCT;
  • Clinically normal appearance of the macula according to clinical judgement, in both eyes. This is examined with Spectralis or Solix OCT;
  • No ocular pathologies, trauma, surgeries (apart from uncomplicated cataract surgery or peripheral laser retinopexy performed at least 6 months before enrollment) in both eyes;
  • Absence of pathologies that can affect visual field in both eyes;
  • No use of drugs interfering with the correct execution of perimetry.

Exclusion criteria

Exclusion Criteria:

  • Glaucoma or glaucoma suspect diagnosis in either eye;
  • Presence or history of ocular hypertension (IOP ≥ 22 mmHg) in either eye;
  • Presence or history of disc hemorrhage in either eye;
  • Presence of amblyopia in either eye;
  • Nystagmus or poor fixation in either eye;
  • Previous laser or any ocular surgery, including uncomplicated cataract surgery performed within 6 months before enrollment in both eyes;
  • Any active infection of anterior or posterior segments in the study eye;
  • Subjects with significant ocular media opacities preventing acquisition of acceptable infrared (IR) fundus image quality in the study eye;
  • Evidence of diabetic retinopathy, diabetic macular edema, or other retinal disease in either eye;
  • Use of any drug that can interfere with the correct execution of MP or that would produce visual field loss;
  • Unable to tolerate ophthalmic imaging;
  • Claustrophobia;
  • Inability to provide .
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
380 participants (estimated)

Study arms

  • Experimental
    Main Arm

    \*) one microperimetric examination with MAIA

    Device: MAIA

Interventions

  • DeviceMAIA

    MAIA is an automatic microperimeter with fundus imaging capabilities that measures retinal sensitivity, fixation stability and locus of fixation, and allows the acquisition of confocal images of the retina, thanks to its confocal scanning imaging system which uses infrared and visible light.

06

What researchers measure

Primary outcomes

  1. To determine the reference normative values of retinal sensitivity for MAIA

    The reference normative values will be determined by using a linear regression model for Mean Sensitivity (MS) as a function of age. The 5th and 10th percentile values will be derived for each age, and will serve as age-adjusted normative data against which compare the MS computed during each test with MAIA

    Time frame: 1 day

Secondary outcomes

  1. To assess the avoidance of Serious Adverse Device Effects with MAIA

    During the clinical investigation, adverse events will be documented, investigated and reported according to the provisions of applicable reporting guidelines, following their criteria and timelines.

    Time frame: through study completion (expected duration: 10 months)

07

Study locations

1 of 3 sites recruiting
  • The Eye Care Institute
    Fort Lauderdale, Florida 33312, United States
    Not yet recruiting
    • Julie Rodman, Professor · Contactrjulie@nova.edu · (954) 262-4274
    • Julie Rodman, Professor · Principal investigator
  • UWA Eye Health Centre of Western Australia
    Perth, Western Australia 6009, Australia
    Not yet recruiting
  • Universitätsspital Basel, Augenklinik
    Basel, CH-4031, Switzerland
    Recruiting
    • Kristina Pfau, PD Dr. med. · Contactkristina.pfau@usb.ch · 78 480 38 37
    • Kristina Pfau, PD Dr. med. · Principal investigator
    • Maximilian Pfau, PD Dr. med. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for May 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 25, 2025
StartActual
Apr 23, 2025
Primary completionEst.
May 1, 2026
CompletionEst.
Jun 1, 2026
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06991127
Lead sponsor
Centervue SpA
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Apr 23, 2025
Primary completion
May 1, 2026 (estimated)
Completion
Jun 1, 2026 (estimated)
Last update
May 25, 2025

Study contacts

Maximilian Pfau, PD Dr. med.
Contact
maximilian.pfau@usb.ch
78 215 42 67 ext. +41
Maximilian Pfau, PD Dr. med.
study chair · Universitätsspital Basel, Augenklinik

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion